Certara upgraded to Buy from Neutral at UBS

UBS analyst Dan Leonard upgraded Certara to Buy from Neutral with an unchanged price target of $16. The firm has increased conviction that the company is “uniquely positioned” to drive further adoption of biosimulation in drug development and cross-sell related software. This combination should restore double-digit sales growth from current “depressed levels,” the analyst tells investors in a research note. UBS says current biopharma challenges have pressured Certara’s growth but appear to have stabilized, are well understood, and have provided an attractive entry point “for a unique asset with structural regulatory tailwinds.”